162 related articles for article (PubMed ID: 30588030)
1. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.
Chen HM; Feng G
Onco Targets Ther; 2019; 12():57-61. PubMed ID: 30588030
[TBL] [Abstract][Full Text] [Related]
2. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review.
Cheng K; Liu X; Chen Y; Zhou K; Li Z
BMC Gastroenterol; 2022 Aug; 22(1):388. PubMed ID: 35978277
[TBL] [Abstract][Full Text] [Related]
3. Effective Treatment of Anlotinib Combined With Chemotherapy in Children With Desmoplastic Small Round Cell Tumor: A Case Series in a Single-center and Literature Review.
Jing XY; Shen CQ; He GQ; Xu RR; Gao J; Guo X
J Pediatr Hematol Oncol; 2024 Apr; 46(3):159-164. PubMed ID: 38408140
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review.
Shi C; Feng Y; Zhang LC; Ding DY; Yan MY; Pan L
BMC Cancer; 2018 Mar; 18(1):338. PubMed ID: 29587657
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib as a molecular targeted therapy for tumors.
Gao Y; Liu P; Shi R
Oncol Lett; 2020 Aug; 20(2):1001-1014. PubMed ID: 32724339
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe.
Deng Z; Liao W; Wei W; Zhong G; He C; Zhang H; Liu Q; Xu X; Liang J; Liu Z
Cancer Cell Int; 2021 Jan; 21(1):37. PubMed ID: 33422069
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
10. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature.
Zhang Y; Wu D; Zhao B; Tian XL; Yao TC; Li F; Liu WF; Shi AP
World J Clin Cases; 2021 Feb; 9(4):919-926. PubMed ID: 33585640
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report.
Zhang K; Wang H; Fang J; Xu Q
Ann Transl Med; 2021 Aug; 9(16):1353. PubMed ID: 34532490
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Ma J; Song Y; Shou J; Bai Y; Li H; Xie X; Luo H; Ren X; Liu J; Ye D; Bai X; Fu C; Qin S; Wang J; Zhou AP
Front Oncol; 2020; 10():664. PubMed ID: 32457838
[No Abstract] [Full Text] [Related]
13. Intra-abdominal desmoplastic small round cell tumor.
Nathan JD; Gingalewsik C; Salem RR
Yale J Biol Med; 1999; 72(4):287-93. PubMed ID: 10907779
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.
Li S
Front Oncol; 2021; 11():664853. PubMed ID: 34094958
[TBL] [Abstract][Full Text] [Related]
15. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F
Thorac Cancer; 2019 Mar; 10(3):551-556. PubMed ID: 30666799
[TBL] [Abstract][Full Text] [Related]
16. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis.
Xu T; Wei C; Zou X; Lu B; Wang Z
Front Oncol; 2021; 11():680818. PubMed ID: 34249723
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report.
Gan Y; Liu P; Luo T
Front Oncol; 2021; 11():775201. PubMed ID: 34858856
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib dramatically improved pulmonary hypertension and hypoxia caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) associated with gastric carcinoma: a case report.
Wang Y; Ning WW; Jin YF; Zhu QQ; Wang ZL; Su N; Chen YB; Huang JA; Chen C
Thromb J; 2023 Mar; 21(1):33. PubMed ID: 36973680
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
